Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
Prospective, multicenter, randomized, placebo-controlled, double-blind clinical trial to evaluate safety and efficacy of candesartan in the prevention of the development of Dilated Cardiomyopathy (DCM) in genetic carriers of a DCM-causing variant without disease expression (asymptomatic)
Full description
Prospective, multicenter, randomized, placebo-controlled, double-blind clinical trial to evaluate safety and efficacy of early administration of candesartan in the prevention of the development of Dilated Cardiomyopathy (DCM) in genetic carriers of a DCM-causing variant without disease expression (asymptomatic).
Randomization will be 1:1 and patients are allocated to candesartan or matching placebo.
Patients will be followed for a 3 years period and efficacy will be demonstrated if candesartan (compared to placebo) prevents either a significant Left ventricular ejection fraction (LVEF) decline of ≥10%, or a ventricular dilatation (left ventricular end-diastolic volume, LVEDV) increase of ≥10% within a 3-years period of follow-up
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
320 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Cristina Avendaño-Solá, MD, PhD; Ana Velasco-Iglesias, Msc,PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal